BTIM Corp. lifted its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.7% in the 4th quarter, Holdings Channel reports. The institutional investor owned 810,344 shares of the company’s stock after acquiring an additional 5,772 shares during the period. Johnson & Johnson makes up approximately 1.7% of BTIM Corp.’s investment portfolio, making the stock its 5th largest position. BTIM Corp.’s holdings in Johnson & Johnson were worth $113,221,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors have also recently added to or reduced their stakes in the company. Landmark Financial Advisors LLC raised its stake in Johnson & Johnson by 0.4% in the 2nd quarter. Landmark Financial Advisors LLC now owns 1,962 shares of the company’s stock valued at $259,000 after purchasing an additional 7 shares during the last quarter. Premier Asset Management LLC grew its holdings in Johnson & Johnson by 0.4% in the 2nd quarter. Premier Asset Management LLC now owns 2,749 shares of the company’s stock valued at $363,000 after buying an additional 12 shares during the period. Lbmc Investment Advisors LLC grew its holdings in Johnson & Johnson by 0.4% in the 2nd quarter. Lbmc Investment Advisors LLC now owns 3,718 shares of the company’s stock valued at $492,000 after buying an additional 14 shares during the period. Halbert Hargrove Russell LLC grew its holdings in Johnson & Johnson by 0.4% in the 2nd quarter. Halbert Hargrove Russell LLC now owns 3,523 shares of the company’s stock valued at $466,000 after buying an additional 15 shares during the period. Finally, Lenox Wealth Management Inc. grew its holdings in Johnson & Johnson by 1.7% in the 2nd quarter. Lenox Wealth Management Inc. now owns 1,457 shares of the company’s stock valued at $193,000 after buying an additional 24 shares during the period. 67.18% of the stock is owned by institutional investors and hedge funds.
Several analysts have commented on the company. Vetr cut Johnson & Johnson from a “hold” rating to a “sell” rating and set a $124.55 price target for the company. in a report on Thursday, April 5th. JPMorgan Chase cut Johnson & Johnson from an “overweight” rating to a “neutral” rating in a report on Tuesday, January 2nd. Zacks Investment Research upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $145.00 price target for the company in a report on Wednesday, April 11th. Deutsche Bank restated a “buy” rating on shares of Johnson & Johnson in a report on Wednesday, April 18th. Finally, Jefferies Group set a $165.00 price target on Johnson & Johnson and gave the company a “buy” rating in a report on Monday, February 26th. Five analysts have rated the stock with a sell rating, eight have given a hold rating and ten have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $142.23.
Shares of NYSE:JNJ opened at $128.01 on Friday. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.41 and a quick ratio of 1.12. Johnson & Johnson has a 1 year low of $122.15 and a 1 year high of $148.32. The stock has a market cap of $338,555.44, a PE ratio of 17.54, a PEG ratio of 1.93 and a beta of 0.74.
Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, April 17th. The company reported $2.06 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.00 by $0.06. The business had revenue of $20.01 billion during the quarter, compared to analysts’ expectations of $19.50 billion. Johnson & Johnson had a return on equity of 30.05% and a net margin of 1.58%. The company’s revenue for the quarter was up 12.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.83 EPS. sell-side analysts forecast that Johnson & Johnson will post 8.13 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 12th. Shareholders of record on Tuesday, May 29th will be issued a $0.90 dividend. This represents a $3.60 dividend on an annualized basis and a yield of 2.81%. The ex-dividend date is Friday, May 25th. This is a boost from Johnson & Johnson’s previous quarterly dividend of $0.84. Johnson & Johnson’s dividend payout ratio is currently 46.03%.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.